Get started
Author

Fiorenza Latteri

Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
2024 · Brigida Anna Maiorano, Massimo Di Maio, et al. · JAMA Network Open · 54
Combined regimen of cisplatin, doxorubicin, and ?-2b interferon in the treatment of advanced malignant pleural mesothelioma
2001 · H�ctor Soto Parra, Lucia Tixi, et al. · Cancer · 51
PDF
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib
2013 · Marcello Tiseo, Massimo Ippolito, et al. · Cancer Chemotherapy and Pharmacology · 29
Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer
2020 · Marco Maria Aiello, Cinzia Solinas, et al. · Frontiers in Oncology · 14
PDF
Primary diffuse malignant peritoneal mesothelioma: Case report and update of therapy
2000 · Diego Piazza, Francesco Caruso, et al. · Journal of Surgical Oncology · 10
P-618 ZD 1839 (Iressa) in elderly patients with progressive pretreated non small cell lung cancer (NSCLC): Results at the Istituto clinico humanitas, Rozzano, Milano
2003 · Raffaele Cavina, Hector J. Soto Parra, et al. · Lung Cancer · 5
Radiotherapy directed to inferior vena cava tumor thrombus among patients with renal cell carcinoma: an illustrative case and review of the literature
2024 · Valentina Zagardo, Francesco Cuccia, et al. · ONCOLOGIE · 4
PDF
Efficacy and Safety of Prolonged Adjuvant Temozolomide Treatment in Glioblastoma: Prospective Study of 81 Patients Undergoing up to 101 Cycles of Treatment
2025 · Giulio Bonomo, Francesco Certo, et al. · Brain Sciences · 3
PDF
A phase II, noncomparative, open label, multicentre, study of AZD9291 in patients with locally advanced or metastatic EGFR mutated “T790M undetectable or unknown” non-small cell lung cancer (stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study).
2017 · Hector J. Soto Parra, Laura Noto, et al. · Journal of Clinical Oncology · 3
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study
2006 · Hector Soto Parra, Raffaele Cavina, et al. · Investigational New Drugs · 3
Phase II, noncomparative, open label, multicenter, study of osimertinib, in patients with locally advanced or metastatic EGFR mutated, T790M undetectable or unknown non-small cell lung cancer (Stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study).
2021 · Hector J. Soto Parra, Laura Noto, et al. · Journal of Clinical Oncology · 2
Short Schedule of Cisplatin and Vinorelbine: A Dose-Finding Study in Non-Small-Cell Lung Cancer
2006 · Paolo Andrea Zucali, Hector Jose Soto Parra, et al. · Oncology · 2
Treatment Perspectives in Advanced Non-Small Cell Lung Cancer
2000 · Héctor Soto Parrà, Fiorenza Latteri, et al. · Tumori Journal · 2
Prospective correlative study of FDG-PET SUV and proteomic profile (VeriStrat) of non-small cell lung cancer patients treated with erlotinib.
2012 · Chiara Lazzari, Marcello Tiseo, et al. · Journal of Clinical Oncology · 1
Activity and safety of CPBev regimen (cisplatinum, pemetrexed, and bevacizumab) as first-line therapy for locally advanced or metastatic adenocarcinoma of the lung: Final results of a phase II study.
2012 · Roberto Bordonaro, Hector Soto-parra, et al. · Journal of Clinical Oncology · 1
Non‐small‐cell Lung Cancer Patients Unsuitable for First‐line Chemotherapy: a New Category of Patients for Clinical Studies?
2005 · Héctor J. Soto Parra, Fiorenza Latteri, et al. · Journal of the American Geriatrics Society · 1
Bladder Cancer
2021 · Hector Josè Soto Parra, Fiorenza Latteri, et al. · UNIPA Springer series
1147P Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in locally advanced or oligometastatic melanoma: Preliminary results
2020 · E. Cocorocchio, L. Pala, et al. · Annals of Oncology
進行非小細胞肺癌における切除修復交差相補性グループ1一塩基多型とニボルマブ【jst・京大機械翻訳】
2020 · Aiello Marco Maria, Solinas Cinzia, et al. · Frontiers in Oncology
P-4 Preliminary results of an intensified 3-day schedule of cisplatin (P) and vinorelbine (V) as induction treatment in prognostically unfavorable locally advanced non-small-cell lung cancer (LA-NSCLC)
2003 · Hector J. Soto Parra, Raffale Cavina, et al. · Lung Cancer
P-619 Analysis of responses to gefitinib (ZD 1839 IressaTM) according to epidermal growth factor receptor (EGFR) expressed as staining intensity or percentage of immunoreactive cells
2003 · Armando Santoro, Hector J. Soto Parra, et al. · Lung Cancer
P-32 Feasibility of combination of cisplatin (C) and gemcitabine (G) in non-small cell lung cancer (NSCLC): Analysis of dose-intensity (DI) and compliance of four different schedules
2003 · Hector J. Soto Parra, Raffaele Cavina, et al. · Lung Cancer
[Stromal tumors of the small intestine. Retrospective analysis of 9 cases surgically treated].
2002 · Francesco Mosca, Antonio Stracqualursi, et al. · PubMed
Works count: 23
Citation count: 185
H-index: 5
I10-index: 5
Year
Topic
Type